A new trading day began on Friday, with Verona Pharma Plc ADR (NASDAQ: VRNA) stock price down -4.44% from the previous day of trading, before settling in for the closing price of $66.26. VRNA’s price has ranged from $11.39 to $74.18 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -39.77%. Meanwhile, its annual earnings per share averaged 153.70%. With a float of $74.53 million, this company’s outstanding shares have now reached $85.13 million.
Let’s determine the extent of company efficiency that accounts for 209 employees. In terms of profitability, gross margin is 94.72%, operating margin of -116.27%, and the pretax margin is -131.25%.
Verona Pharma Plc ADR (VRNA) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Verona Pharma Plc ADR is 12.34%, while institutional ownership is 71.17%. The most recent insider transaction that took place on May 06 ’25, was worth 1,014,343. In this transaction Chief Medical Officer of this company sold 114,984 shares at a rate of $8.82, taking the stock ownership to the 2,546,472 shares. Before that another transaction happened on May 06 ’25, when Company’s Officer proposed sale 14,373 for $72.25, making the entire transaction worth $1,038,449.
Verona Pharma Plc ADR (VRNA) Recent Fiscal highlights
According to the Wall Street analysts, stocks earnings will be around 153.70% per share during the next fiscal year.
Verona Pharma Plc ADR (NASDAQ: VRNA) Trading Performance Indicators
Here are Verona Pharma Plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 8.73. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 45.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.04, a number that is poised to hit -0.00 in the next quarter and is forecasted to reach 1.08 in one year’s time.
Technical Analysis of Verona Pharma Plc ADR (VRNA)
Looking closely at Verona Pharma Plc ADR (NASDAQ: VRNA), its last 5-days average volume was 1.44 million, which is a drop from its year-to-date volume of 1.5 million. As of the previous 9 days, the stock’s Stochastic %D was 24.01%. Additionally, its Average True Range was 3.70.
During the past 100 days, Verona Pharma Plc ADR’s (VRNA) raw stochastic average was set at 69.00%, which indicates a significant increase from 25.05% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.31% in the past 14 days, which was lower than the 59.21% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $63.89, while its 200-day Moving Average is $45.05. However, in the short run, Verona Pharma Plc ADR’s stock first resistance to watch stands at $66.51. Second resistance stands at $69.71. The third major resistance level sits at $71.56. If the price goes on to break the first support level at $61.47, it is likely to go to the next support level at $59.62. Now, if the price goes above the second support level, the third support stands at $56.42.
Verona Pharma Plc ADR (NASDAQ: VRNA) Key Stats
With a market capitalization of 5.39 billion, the company has a total of 81,080K Shares Outstanding. Currently, annual sales are 42,280 K while annual income is -173,420 K. The company’s previous quarter sales were 76,260 K while its latest quarter income was -16,320 K.
